en · de · es · fr · pt
creatine-notes.peptides6908.com › Info › Compound Identity And Development History — Field Notes

Compound Identity And Development History — Field Notes

By Editorial Desk · published 2025-12-23 · last reviewed 2026-01-15 · Info

A practical reference on GHRH receptor: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.

Reviewed 2026-01-15. Anything still debated is marked as such rather than presented as settled.

Compound Identity and Development History

The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.

Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.

CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.

Receptor Action and Clearance

Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.

Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.

Cjc-1295 at a glance

PropertyValueNotes
Molecular formulaC152H252N44O42Cited for the form without the drug affinity complex
Molecular weightAbout 3368 DaReported value for modified GRF(1-29)
AppearanceWhite to off-white powderLyophilised solid as usually supplied
SolubilitySoluble in water and polar solventsClarity depends on purity and salt content
Typical storage-20 C or below, dryProtect from light and repeated warming cycles

Background and Naming Conventions

Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.

CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.

Related pages on this site

Molecular Background and Naming

The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.

CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.

Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.

Handling Storage and Quality Control

Batch-to-batch consistency depends on solid-phase peptide synthesis and subsequent purification. Coupling efficiency, resin choice, and cleavage conditions all affect the final profile. Counter-ion content and moisture can shift the apparent mass of a batch. Documentation typically includes a certificate of analysis with chromatograms and spectra. Independent verification by a second laboratory is sometimes requested. Whether a given certificate reflects the actual vial contents depends on chain of custody. Analytical methods themselves carry uncertainty that should be stated alongside results.

Lyophilized material is typically stored at minus twenty degrees Celsius or lower. Keeping the vial dry and protected from light preserves peptide integrity. Repeated freeze-thaw cycles can cause aggregation or loss of activity. Once dissolved, solutions are generally kept at two to eight degrees Celsius. Stability data for reconstituted solutions vary, and long-term behavior is not fully established. Working aliquots reduce the number of times a stock container is opened.

Reverse-phase high-performance liquid chromatography is the standard tool for purity assessment. The technique separates the target peptide from truncated or modified byproducts. Mass spectrometry confirms molecular weight and supports sequence verification. Electrospray ionization and matrix-assisted laser desorption are both used. Amino acid analysis provides an independent check on composition. Purity values are commonly reported as area percentage from the chromatogram. Residual trifluoroacetate and water content are also measured in many quality programs.

Background and Receptor Mechanism

At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.

CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.

Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.

Background from the literature

== Structure == The fundamental structure of a cerebroside is ceramide. Monoglycosyl and oligoglycosylceramides having a mono or polysaccharide bonded glycosidically to the terminal OH group of ceramide are defined as cerebrosides. Sphingosine is the main long-chain base present in ceramide. Galactosylceramide is the principal glycosphingolipid in brain tissue. Galactosylceramides are present in all nervous tissues, and can compose up to 2% dry weight of grey matter and 12% of white matter. They are major constituents of oligodendrocytes. Glucosylceramide is found at low levels in animal cells such as the spleen, erythrocytes, and nervous tissues, especially neurons. Glucosylceramide is a major constituent of skin lipids, where it is essential for lamellar body formation in the stratum corneum and to maintain the water permeability barrier of the skin. Glucosylceramide is the only glycosphingolipid common to plants, fungi and animals. It is usually considered to be the principal glycosphingolipid in plants. It is a major component of the outer layer of the plasma membrane. Galactosylceramides have not been found in plants. Monogalactosylceramide is the largest single component of the myelin sheath of nerves. Cerebroside synthesis can therefore give a measurement of myelin formation or remyelination. The sugar moiety is linked glycosidically to the C-1 hydroxyl group of ceramide, such as in lactosylceramide. Cerebrosides containing a sulfuric ester (sulfate) group, known as sulfatides, also occur in the myelin sheath of nerves.

Endotoxins are the lipid portions of lipopolysaccharides that are part of the outer membrane of the cell wall of gram-negative bacteria. Endotoxins are released when the bacteria lyses, which is why after antibiotic treatment, symptoms can worsen at first as the bacteria are killed and they release their endotoxins. Exotoxins are secreted into the surrounding medium or released when the bacteria die and the cell wall breaks apart.

is called as the Stokes hypothesis. The validity of Stokes hypothesis can be demonstrated for monoatomic gas both experimentally and from the kinetic theory; for other gases and liquids, Stokes hypothesis is generally incorrect. With the Stokes hypothesis, the Navier–Stokes equations become

=== Everton bid === In September 2023, 777 Partners agreed to buy Farhad Moshiri's 94.1% shareholding in English Premier League team Everton F.C. In April 2024, with the deal not complete and after the 777-owned Australian airline Bonza entered voluntary administration, Everton called upon the services of insolvency advisers Teneo. Amid lawsuits against 777 Partners in other countries, the Everton Shareholders' Association wrote to Moshiri requesting that he terminate the deal. 777 enlisted B. Riley Financial for advice to complete the deal. According to 777's own lawyers, Wander and Pasko resigned as managers of the company on May 6, 2024, but remained as its 100% owners. On June 1, 2024, the deadline for the deal to be completed expired.

In several countries, the illegal drug trade is thought to be directly linked to violent crimes such as murder and gun violence. This is especially true in all developing countries, such as Honduras, but is also an issue for many developed countries worldwide. In the late 1990s in the United States, the Federal Bureau of Investigation estimated that 5% of murders were drug-related. In Colombia, drug violence can be caused by factors such as the economy, poor governments, and no authority within law enforcement. After a crackdown by US and Mexican authorities in the first decade of the 21st century as part of tightened border security in the wake of the September 11 attacks, border violence inside Mexico surged. The Mexican government estimated that 90% of the killings were drug-related. A report by the UK government's Drug Strategy Unit that was leaked to the press, stated that due to the expensive price of highly addictive drugs heroin and cocaine, drug use was responsible for the great majority of crime, including 85% of shoplifting, 70–80% of burglaries and 54% of robberies. It concluded "[t]he cost of crime committed to support illegal cocaine and heroin habits amounts to £16 billion a year in the UK"

Sources: en.wikipedia.org

Further detail

Sigma-Aldrich Fine Chemicals (SAFC) is the fine chemical supply branch of Sigma-Aldrich specializing in raw materials for cell culture products; customized services for raw materials, manufacturing of active pharmaceutical ingredients. Sigma Life Science provides products such as custom DNA/RNA oligos; custom DNA and LNA probes; siRNA; isotopically-labelled peptides and peptide libraries. Sigma Advanced Genetic Engineering (SAGE) Labs was a division within Sigma-Aldrich that specializes in genetic manipulation of in vivo systems for special research and development applications. It was formed in 2008 to investigate zinc finger nuclease technology and its application for disease research models. Located in St. Louis, Missouri, SAGE Labs have developed knockout rats for the study of human diseases and disorders (such as autism), which are sold for up to US$95,000. SAGE also announced its first successful effort in creating a "knockout rabbit". Its facilities include a specific pathogen free, biosecure vivarium as well as research and development labs. SAGE Labs was acquired by Horizon Discovery Group in 2014. Carbolabs produces research quantities of chemicals produced by phosgenation reactions. The company was acquired in 1998. BioReliance provides testing and manufacturing services to pharmaceutical and biopharmaceutical companies that span the product cycle from early pre-clinical development to licensed production. The company was acquired by Sigma Aldrich in January 2012.

The head and teeth shape of bats can vary by species. In general, megabats have a fox-like appearance with long snouts and ears, hence their nickname of "flying foxes". Among microbats, longer snouts are associated with nectar-feeding, while vampire bats have reduced snouts. The number of teeth in bats can vary between 38 teeth in small, insect-eating species and as low as 20 in vampire bats. A diet of hard-shelled insects requires fewer but larger teeth along with longer canines and more robust lower jaws. In nectar-feeding bats, the canines are long, while the cheek teeth are reduced. In fruit-eating microbats, the cusps of the cheek teeth are adapted for crushing. The upper incisors of vampire bats lack enamel, which keeps them razor-sharp. The bite force of small bats is generated through mechanical advantage, allowing them to bite through the hardened armour of insects or the skin of fruit.

Several common plants are known to absorb fluoxetine. Several crops have been tested, and Redshaw et al. 2008 find that cauliflower absorbs large amounts into the stem and leaf but not the head or root. Wu et al. 2012 find that lettuce and spinach also absorb detectable amounts, while Carter et al. 2014 find that radish (Raphanus sativus), ryegrass (Lolium perenne) – and Wu et al. 2010 find that soybean (Glycine max) – absorb little. Wu tested all tissues of soybean and all showed only low concentrations. By contrast various Reinhold et al. 2010 find duckweeds have a high uptake of fluoxetine and show promise for bioremediation of contaminated water, especially Lemna minor and Landoltia punctata. Ecotoxicity for organisms involved in aquaculture is well documented. Fluoxetine affects both aquacultured invertebrates and vertebrates, and inhibits soil microbes including a large antibacterial effect.

==== Tax credit for seniors ==== The law permanently eliminates the personal exemption, which had been temporarily eliminated by the Tax Cuts and Jobs Act of 2017. It offers a temporary tax deduction, set to expire in 2028, of up to $6,000 for seniors. The deduction phases out for individuals with modified adjusted gross income (MAGI) exceeding $75,000 (or $150,000 for married couples). According to the Council of Economic Advisors, this would result in 88% of seniors being able to claim enough deductions to clear their Social Security tax burden, up from 64% under prior law. A taxpayer is not required to itemize their tax deductions in order to take the tax deduction.

He noted the remarkable stability of temperatures and the mildness of the equatorial climate at sea. The tranquil progress was disrupted when a typhus epidemic broke out on board, a common danger in the cramped and unsanitary conditions of ships at the time. Typhus, spread by lice, quickly incapacitated several passengers and crew members. Captain Cagigal remained indifferent to the outbreak, refusing preventative measures, while the ship’s surgeon relied on ineffective treatments based on erroneous theories of disease. Fear spread among the passengers, including Humboldt, who regretted not having quinine bark among his supplies. On July 8, a sailor gravely ill with the disease was brought on deck for last rites but began to recover, reinforcing the surgeon’s misguided confidence in his methods. Another passenger, a young Asturian man pressured into emigrating to Cuba, succumbed to the disease despite his friend’s devoted care, leaving the latter bereft and anxious about his prospects. The young man’s death was marked by a somber shipboard burial, deepening Humboldt’s melancholy as the ship neared the Caribbean islands. Spurred by the worsening epidemic, the captain decided to bypass Havana and proceed directly to Cumana in Venezuela, forcing all passengers to remain aboard. Nearing Cumana on July 15, the Pizarro encountered local Guayqueria, who approached after initial hesitation. The Natives, tall and strong, offered the crew gifts and information about the local geography. Their leader, Carlos del Pino, agreed to pilot the ship through safe channels.

Sources: en.wikipedia.org

Frequently asked questions

What is CJC-1295?

It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.

Is CJC-1295 an approved medicine?

No regulatory agency has approved CJC-1295 for clinical use. Human trials were conducted in the 2000s, but the development programme was discontinued before any marketing application succeeded. Material sold today is offered as a research chemical, and its purity depends on the supplier.

How does it differ from sermorelin?

Sermorelin is an unmodified fragment of growth hormone-releasing hormone and is cleared quickly. CJC-1295 contains substitutions that resist breakdown, and the form with a drug affinity complex persists much longer. Both act at the same receptor but differ substantially in duration of action.

Which receptor does the compound target?

It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.

Network